Stemcells, Was haltet Ihr davon - 500 Beiträge pro Seite

[winthorp]

hi,

brauche infos darüber.

[Honsek]

Ich denke das wird noch der Brüller.
Aber mal im ernst.

Ich denke das ganze hat Zukunft einfach ein paar Stück ins Depot und in 2 Jahren reich sein
MfG

[sevruga]

hi,

ich persönlich habe so langsam die schnautze voll und werde mit 62% verlust rausgehen.
heute in ny wieder über 13% runter.
da bin ich förtsch echt auf den leim gegangen...

StemCells, Inc. Reports Third Quarter Financial Results

SUNNYVALE, Calif., Nov 14, 2000 (BW HealthWire) -- StemCells, Inc. (Nasdaq:
STEM) today reported financial results for its third quarter ended September 30,
2000. Net loss for the third quarter was $2.5 million, or $0.13 per share,
compared with a net loss of $6.7 million, or $0.36 per share, in the same
quarter in 1999. The change was primarily due to the restructuring of the
Company that began a year ago, including the reduction in staff, change in focus
of research and development, and move from Rhode Island to Sunnyvale,
California. The Company had no revenues from collaborative relationships, in
either the three months ended Sept 30, 2000 or the same period in 1999.

For the three months ended September 30, 2000, research and development expenses
were $1.1 million, down $446,932 or 28% from the comparable quarter last year.
General and administrative expenses were $840,490, down $186,867 or 18% for the
same quarter in 1999. The changes were primarily due to the Company`s
restructuring. Wind-down expenses related to our ECT research and relocation of
our corporate headquarters from Rhode Island to Sunnyvale, California for the
three-month period ended September 30, 2000 and 1999 was $574,317 and $4,078,034
respectively. The $574,317 was in addition to a reserve of $1,934,569 created in
the fourth quarter of 1999 for wind-down expenses related to the first half of
year 2000.

Cash, cash equivalents and short-term investments totaled $7.2 million on
September 30, 2000 compared to $6.3 million on September 30, 1999. Stockholders
equity as of September 30, 2000 was $37.5 million. The increase of approximately
$9.5 million from the previous quarter reflects an $8 million increase in the
value of its ownership of Modex Therapeutics common stock, the $5.0 million sale
of StemCells common stock to Millennium Partners, L.P. less $1.25 million stock
subscription receivable and $0.25 million issuance cost, plus the
exercise/valuation of stock options of $0.5 million and offset by an operating
loss of $2.5 million. The value of the Company`s holding of Modex Therapeutics,
however, was approximately $7.5 million less on November 13, 2000 than on
September 30, when it was valued for the purposes of the quarterly report. This
was primarily due to the decline in the price of the stock from 372 Swiss Francs
per share on September 30 to 275 Swiss Francs per share on November 13.

StemCells is focused on the discovery, development, and commercialization of
stem cell-based therapies to treat diseases of the central nervous system,
pancreas, and liver. The Company`s stem cell programs seek to repair or
repopulate neural, pancreatic, and liver tissue that has been damaged or lost as
a result of disease or injury. On May 23, 2000 the name of the Company was
changed to StemCells, Inc. from CytoTherapeutics, Inc., by vote of the
shareholders at the Company`s Annual Meeting.

Statements in this press release, other than statements of historical fact,
constitute forward-looking statements regarding, among other things, the future
business operations of StemCells, Inc. The Company`s actual results may vary
materially from those contemplated in the forward looking statements due to
risks and uncertainties to which the Company is subject, including uncertainties
regarding the Company`s ability to obtain the capital resources needed to
conduct the research, preclinical development and clinical trials necessary to
develop products and obtain regulatory approvals; the fact that the Company`s
stem cell technology is at the preclinical stage and has not yet led to the
development of any proposed product; the future market value of its stock
holdings in Modex; uncertainties regarding the Company`s continuing obligations
in regard to its former Rhode Island facilities, the uncertainty whether the
Company will achieve revenues from product sales or become profitable; and
others that are described in Exhibit 99 to the Company`s Annual Report on Form
10-K , as amended, entitled "Cautionary Factors Relevant to Forward Looking
Statements".


CONTACT: StemCells, Inc.
Ann Tsukamoto, Vice President, Scientific Operations
408/731-8670
or
Susan E. Atkins & Associates
Media Contact:
Anette Breindl, 858/860-0266

[Honsek]

Hi,
Es muß erst noch weh tun dafür ist dann die Freude umso größer
MfG

[hilky2]

ich denke auch, daß sich diese geschichte mal "mausern" wird.
letzten endes spielt die ethik nicht so die rolle. technik hat sich ja am ende immer durchgesetzt.
bin leider auch zu früh eingestiegen bei 5,3 euro, werde aber jetzt wohl nochmal nachkaufen. bei der volatilität kann man mal die ein oder anderen prozente mitnehmen,
ich hoffe wir setzten auf des richtige pferd.

tschau hilky

[priestbroker]

hallo,

bin auch in stem investiert und verfolge den wert seit einiger
zeit auch auf dem ragingbull-board. bin von stem überzeugt.

gruß
priest

[Kamps]

ja ja bin bei 10.80 Euro eingestiegen hoffentlich seh ich die iirgendwann wieder

[Forum]

Da gab es gestern wohl ein OK zum Klonen von menschlichen Stammzellen. Empörung in Bayern !!!

Habe lediglich ein paar Wortfetzen bei NTV gehört.

[Goethe1971]

[LMeister7]

Neue Besen kehren gut!
Neuer CEO bei Stemmcells

StemCells, Inc. Names Martin McGlynn New President and Chief Executive Officer; Former Pharmadigm CEO to Lead Executive Management Team Effective January 15, 2001

SUNNYVALE, Calif.--(BUSINESS WIRE)--Jan. 4, 2001--StemCells, Inc. (Nasdaq: STEM) announced today that effective January 15th, Martin McGlynn will become President and CEO of the Company.

McGlynn brings several decades of international experience in the Life Sciences industry to his position. Prior to joining StemCells, Inc., he was President and CEO of Pharmadigm, Inc., a privately held company in Salt Lake City, Utah, which is engaged in research and development in the fields of inflammation and genetic immunization. During his time at Pharmadigm, McGlynn took the company through four rounds of financing, raising in excess of $50 million in private and venture capital. Mr. McGlynn`s prior experience includes President of Anaquest Inc., the Pharmaceutical Products Division of BOC Health Care and Vice President, Abbott International and President and General Manager of Abbott Canada Ltd.

"We are extremely pleased that Martin is joining us," said John Schwartz, Chairman of the Board of Directors of StemCells, Inc. "We believe his experience and leadership skills make him ideal for StemCells at this point. We are also grateful to George Dunbar for the leadership he has provided the Company as it turned its focus to its core business of stem cell technology and for his continued involvement with the Company during our search for a new CEO." Mr. Dunbar has been Acting President and CEO of StemCells since February 2000.

Mr. McGlynn is a native of Dublin, Ireland and began his Life Sciences career at Becton Dickinson Ireland, Ltd. He holds a Bachelor of Commerce from University College Dublin, and diplomas in Industrial Engineering and Production Planning from the Irish Institute of Industrial Engineering and the University of Birmingham, respectively.

StemCells Inc. is a company engaged in the use of stem cell technology in the treatment of diseases characterized by damage to, or degeneration of, the central nervous system (CNS), liver, pancreas and other tissue.

Statements in this press release other than statements of historical facts constitute forward looking statements regarding, among other things, the future business operations of StemCells, Inc., or of StemCells California, Inc., its wholly-owned subsidiary (collectively, "the Company"). The Company`s actual results may vary materially from those contemplated in the forward looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company`s ability to obtain the capital resources needed to conduct the research, preclinical development and clinical trials required to develop products and obtain regulatory approvals; the fact that the Company`s stem cell technology is at the pre-clinical stage and has not yet led to the development of any proposed product; the risk that any products that may be generated in the future in the Company`s stem cell programs may not prove clinically safe or effective or may cause tumors or other adverse side effects; the uncertainty whether the Company will achieve revenues from product sales or become profitable; and other risks and uncertainties described in Exhibit 99 to the Company`s Annual Report on Form 10-K entitled "Cautionary Factors Relevant to Forward Looking Statements."

CONTACT: StemCells Inc.
Ann Tsukamoto, Vice President, Scientific Operations
408/731-8670
or
Susan E. Atkins & Associates
Anette Breindl, 858/860-0266

Copyright 2001, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire`s members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
Home | About Nasdaq | Feedback | Help & Reference
Equity & Index Options | Site Map, Index, Tour, Search

Mr. Mc.Glynn scheint seinen Job gut zu machen! Scheint reichlich Erfahrung bei anderen Bio`s gesammelt zu haben.
Vielleicht hilft das dem arg gebeutelten Kurs auf die Sprünge. Aber wichtig ist bei solchen Werten natürlich
dranzubleiben!
Gruß
LM7

[Mattek]

???????????????????????

seit 45 Minuten Bid 2 29/32 (50) und Ask 2 15/16 (1)

Rec. Time Action Price Volume Exch.
11:20:00 AM Trade (at Ask) 2 15/16 200 Nasdaq NM
11:19:29 AM Trade (at Ask) 2 15/16 1000 Nasdaq NM
11:18:43 AM Trade (at Ask) 2 15/16 1000 Nasdaq NM
11:13:46 AM Trade (at Ask) 2 15/16 800 Nasdaq NM
11:13:44 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:13:44 AM Trade (at Ask) 2 15/16 300 Nasdaq NM
11:12:39 AM Trade (at Ask) 2 15/16 500 Nasdaq NM
11:12:28 AM Trade (at Ask) 2 15/16 300 Nasdaq NM
11:12:19 AM Trade (at Ask) 2 15/16 3000 Nasdaq NM
11:09:11 AM Trade (at Ask) 2 15/16 500 Nasdaq NM
11:09:10 AM Trade (at Ask) 2 15/16 400 Nasdaq NM
11:08:50 AM Trade (at Ask) 2 15/16 500 Nasdaq NM
11:06:42 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:06:34 AM Trade (at Ask) 2 15/16 400 Nasdaq NM
11:06:31 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:06:30 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:06:28 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:06:28 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:05:55 AM Trade (at Ask) 2 15/16 100 Nasdaq NM
11:05:48 AM Trade (at Ask) 2 15/16 400 Nasdaq NM

usw.

Jemand Neuigkeiten zu Stemmies ???

[malandro01]

ich persönlich halte mehr von "geron" (902213)
sie sind marktführer in der stammzellenforschung und eines
der führenden unternehmen in der klontechnologie.

[Dr.Jeckill]

Anliegend mal wieder eine interessante Pressemitteilung :

Wednesday January 10, 6:02 am Eastern Time
Press Release
StemCells, Inc. Sells Modex Therapeutics, Ltd. Shares
SUNNYVALE, Calif.--(BW HealthWire)--Jan. 10, 2001--StemCells, Inc. (Nasdaq: STEM - news) announced today that it has sold a portion of their investment in the Swiss company, Modex Therapeutics, Ltd. (SWX New Market: MDXN).

StemCells, Inc. is part of a group of pre-IPO shareholders that participated in a secondary offering of shares by Modex to international institutional investors. StemCells, Inc. sold 22,631 shares at a net price of 182.00 CHF (Swiss francs) per share. This translates to approximately $2.5 million US. StemCells, Inc. and the other selling shareholders have agreed to an additional lock-up period of three months on their remaining shares from the date of the secondary offering.

StemCells, Inc., is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the central nervous system, liver, and pancreas. The Company`s stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.

Statements in this press release other than statements of historical facts constitute forward looking statements regarding, among other things, the future business operations of StemCells, Inc., or of StemCells California, Inc., its wholly-owned subsidiary (collectively, ``the Company``). The Company`s actual results may vary materially from those contemplated in the forward looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company`s ability to obtain the capital resources needed to conduct the research, preclinical development and clinical trials required to develop products and obtain regulatory approvals; the fact that the Company`s stem cell technology is at the preclinical stage and has not yet led to the development of any proposed product; the risk that any products that may be generated in the future in the Company`s stem cell programs may not prove clinically safe or effective or may cause tumors or other adverse side effects; the uncertainty whether the Company will achieve revenues from product sales or become profitable; and other risks and uncertainties described in Exhibit 99 to the Company`s Annual Report on Form 10-K entitled ``Cautionary Factors Relevant to Forward Looking Statements.``


--------------------------------------------------------------------------------
Contact:

StemCells, Inc.
George Koshy, 408/731-8670, ext. 137
or
Susan E. Atkins & Associates
Anette Breindl, 858/860-0266

[Goethe1971]

...am chart kann man sehen, das der Wert gerade dabei ist in eine steile Aufwärtsbewegung überzugehen, 100-150% könnten in den nächsten Wochen drin sein.

[priestbroker]

stem wird erst nochmal korrigieren, es sei denn amgn
zieht den gesamten biosektor mit nach oben

gruß

[Goethe1971]

[Roland.2000]

Hi,

Stemcells hatte ich schon im Januar 2000 im Depot und dann glücklicherweise für 18 € verkauft. Wunderbar.

Bin jetzt aber wieder eingestiegen und warte auf neue Kurssteigerungen.

Potential hat die Aktie auf jeden Fall.

Dafür braucht man nicht dieses dumme Geschwätz der Telebörse, auch wenn sie 100% verspricht !

[FLOTSAM_AND_JETSAM_US]

Neues von STEM: Mäuse mit menschlichen Gehirnzellen !!
"Strange"


Friday February 23, 9:17 pm Eastern Time
U.S. scientists craft mouse with human brain cells
By Andrew Quinn

SAN FRANCISCO, Feb 23 (Reuters) - U.S. researchers have produced laboratory mice with human brain cells, marking a potential step toward developing treatments for human brain disease like Alzheimer`s but promising to fuel fresh debate over the evolving ethics of bioengineering.

The research at California biotechnology company StemCells Inc (NasdaqNM:STEM - news). breaks new ground by demonstrating that human brain stem cells can be induced to grow within a mouse`s skull, scientists said on Friday.

``We are not recreating a human brain. We`re really just trying to understand how these stem cells can function, and how they can be used in the treatment of specific diseases,`` said Ann Tsukamoto, vice president of scientific operations at StemCells Inc.

Irving Weissman, a Stanford university professor involved in the two-year research project, said the next step could be to produce mice with brains made up almost entirely of human cells -- although he said there would have to be a thorough ethical review before this step is taken.

``You would want to ask the ethicist what percentage of the brain would be human cells before you start worrying, and if you start worrying, what would you start worrying about,`` Weissman said.

The California study involved isolating human stem cells in the laboratory and then introducing them into mice. As the mice matured, the human stem cells -- ``master cells`` that can develop into any other type of cell -- grew into a full range of specialized cells throughout each mouse brain.

``It looks like human cells can follow the developmental instructions put in by the mouse brain. They are making human components in what is clearly a mouse brain,`` Weissman said.

The researchers believe that these mice could be used to test treatments for human brain diseases such as Parkinsons and Alzheimer`s, although these tests have not yet been undertaken.

Tsukamoto added that the experiment also demonstrated that StemCell Inc`s process for isolating and developing human stem cells was viable, and that cell banks could be established for future transplantation into humans.

``We`re of course moving this into the development phase, and looking at which disease indications these cells would be best used for in preclinical trials,`` she said.

Both scientists stressed that their research, while marking a new breakthrough in the controversial world of stem cell research, was in no way aimed at blurring the lines between human and animal.

But Weissman added that he had already requested a review panel to look at the research to determine if there may be ethical problems in taking the work further.

``It is not not the objective to go make mice with human brains,`` Weissman said. ``(But) it is in the domain of the ethicists, not the experimenters, to figure out what our limits are.``

[Roland.2000]

Hier nochmal ein interessanter Artikel über Stemcells:

Wissenschaft / US-Erfolg bei Mäusen


Hirnzellen verpflanzt
US-Forscher haben erstmals Mäuse mit menschlichen Hirnzellen gezüchtet. Sie wollen an den Tieren Mittel gegen Nervenleiden wie Alzheimer untersuchen.
New York· Die Biotech-Firma Stemcells Inc. in Sunnyvale (Kalifornien) teilte gestern via Internet mit, dass Mäusen menschliche Stammzellen ins Hirn gepflanzt worden seien, die dort die Funktion von Hirnzellen übernahmen.

Obwohl erst seit drei Jahren bekannt, sind Stammzellen die Hoffnung von Ärzten und Patienten in aller Welt. Forscher glauben, mit diesem Zelltyp einmal gegen Nervenkrankheiten und organische Leiden wie Herz- und Nierenversagen angehen zu können. Manche hoffen, dass Stammzellen selbst Querschnittsgelähmten wieder auf die Beine helfen können.

Die kalifornische Studie, an der auch Forscher der angesehenen Stanford Universität in Palo Alto beteiligt waren, beobachtete den Werdegang der transplantierten Stammzellen im Hirn von Mäusen. Nach Angaben des Unternehmens entwickelten sie sich zu einer Palette spezialisierter Hirnzellen.

Die Wissenschaftler betonen, dass sie mit ihrer Forschung einzig und allein nach Therapien gegen Nervenleiden wie Alzheimer suchen. Das Unternehmen will von einer unabhängigen Kommission die ethische Rechtmäßigkeit seiner Versuche prüfen lassen.

[Roland.2000]

Muss mich korrigieren. Mittlerweile sind wir bei +25%.

Das wird Stemcells ganz nach vorne bringen.

[sevruga]

+42 % !!!! so ein tag, so wunderschön...

StemCells, Inc. Announces Move to Expanded Facilities, Board Changes

SUNNYVALE, Calif., Feb 26, 2001 (BW HealthWire) -- StemCells, Inc. (Nasdaq:
STEM) announced today that the Company has entered a 5-year lease for a 40,000
square foot facility in a strategic investment to accelerate growth in stem cell
research and development. The state of the art facility, located in the Stanford
Research Park in Palo Alto, CA, includes extensive vivarium space as well as
laboratories, offices, and a GMP (Good Manufacturing Practices) suite,
signifying that the facility can be used to manufacture materials for clinical
trials. The new facility will better enable the Company to achieve its goal of
utilizing genetically unmodified human stem cells for the treatment of disorders
of the nervous system, liver, and pancreas.

"Our expanding endeavors require more space for both research and development,"
said Martin McGlynn, President and CEO of StemCells, Inc. "Our research programs
in neural and liver stem cells are growing, and we will now be able to bring our
pancreatic stem cell program in house, rather than relying solely on
collaborative work performed elsewhere. As the Company progresses toward the
development phase of our neural program, the GMP suite, which is suitable for
process development and pilot scale manufacturing of stem cells, will be
invaluable."

The Company also announced that McGlynn, who became President and CEO of
StemCells, Inc. on January 15, 2001, has been appointed to the Company`s Board
of Directors as of February 6, 2001. "We welcome Martin to the Board of
Directors," commented John Schwartz, Chairman of the Board. "His strong
management experience in executive positions in the pharmaceutical industry
enhances the Board`s composition, and will benefit the Company and the
shareholders."

StemCells Inc. is a biotechnology company focused on the discovery, development
and commercialization of stem cell-based therapies to treat diseases of the
central nervous system, liver, and pancreas. The Company`s stem cell programs
seek to repair or repopulate neural or other tissue that has been damaged or
lost as a result of disease or injury.

Statements in this press release other than statements of historical facts
constitute forward looking statements regarding, among other things, the future
business operations of StemCells, Inc., ("the Company"). The Company`s actual
results may vary materially from those contemplated in the forward looking
statements due to risks and uncertainties to which the Company is subject,
including uncertainties regarding the Company`s ability to obtain the capital
resources needed to conduct the research, preclinical development and clinical
trials necessary for regulatory approvals; the fact that the Company`s stem cell
technology is at the pre-clinical stage and has not yet led to the development
of any proposed product; the uncertainty whether any products that may be
generated in the future in the Company`s stem cell programs will prove
clinically effective and not cause tumors or other side effects; the uncertainty
whether the Company will achieve revenues from product sales or become
profitable; and others that are described in Exhibit 99 to the Company`s Annual
Report on Form 10-K entitled "Cautionary Factors Relevant to Forward Looking
Statements."


CONTACT: StemCells, Inc.
Martin McGlynn,President and CEO, 408/731-8670
or
Susan E. Atkins & Associates
Anette Breindl, 858/860-0266

[Mattek]

und dann die hände zum himel, nun lasst uns fröhlich sein. meinetwegen können die auch ärsche mit ohren züchten. hauptsache die phantasie stimmt (sorry, war schon mal nüchterner).

Stemies, make your day


helau,
mattek

[Goethe1971]

Heute +40% da kann man nicht meckern.

[FLOTSAM_AND_JETSAM_US]

NEWS out :

Thursday March 1, 5:59 am Eastern Time

StemCells, Inc. Announces Receipt of NIH Funding

SUNNYVALE, Calif.--(BW HealthWire)--March 1, 2001--StemCells, Inc. (Nasdaq: STEM - news) announced that it has been awarded a two year, $300,000 per year grant from the NIH`s Small Business Innovation Research (SBIR) office.

``We are delighted to receive this funding, which will fund further work in our liver stem cell program,`` commented Martin McGlynn, President and CEO of StemCells, Inc. StemCells Inc. has been focused on identifying human liver stem and progenitor cells as a potential cell based therapeutic in the area of liver disease. As part of this work, scientists at the Company have identified conditions that allow an early liver cell to grow in culture. In collaboration with virologist Dr. Jeffrey Glenn, at Stanford University, they have also shown that these cells can be infected by a human hepatitis virus.

The aim of the SBIR grant is to further characterize the human cells that can be infected by the virus. In addition, they hope to develop a small animal model using these cells that can be infected by human hepatitis viruses to develop assays for the disease, which is a growing public health problem in the United States. ``Such an animal model could lead to the discovery and testing of better therapeutics for the detection, treatment, or prevention of this prevalent infectious agent,`` commented Eric Lagasse, Director of Liver Cell Research at StemCells, Inc. Hepatitis C is the most common blood-borne infection in the US, affecting over 4 million people. Currently there are no vaccines or drugs that specifically target the hepatitis C virus.

StemCells Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the central nervous system, liver, and pancreas. The Company`s stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.

[Mattek]

@ Danke Flotsam... (habe ich auch mal gerne gehört) für die schnelle Reinnahme der Meldung.

Wichtiger m.E. als die Mittel von über 1,2 Mio. ist auch noch mal der Hinweis über den dramatischen Anstieg von Hepatitis-Fällen und damit die Wichtigkeit der Forschungsarbeit von Stem Cells.

Gruß an alle Stemmies,
MatteK

[Forum]

Liegen lassen und sich nicht nur über 50 % freuen !!

Gruß

[taunusmusik]

Ob das sinnvoll ist, die Stemmless zu diesem Kurs zu kaufen. Ich hatte sie mal vor 9 Monaten zu 4,80 und dann für 12 verkauft.
Nehme gerne Deine Meinung unter meiner e-mal auf: [e-mail]

Danke!!! Müßte natürlich nmoch heute sien. Es kommt im TV eine Meldung (heute), habe sie leider nicht richtig hören können.

[MadMoney]

Hi, hatte stem letztes jahr im august/september, hab nen ganz guten riss gemacht, war bei 4,51 rein und bei 8 wieder raus. hab sie die ganze zeit auf der watchlist. wie viele schon schrieben, ist die aktie ein gutes langfristinvest, aber zur zeit eher finger weg. erst wenn sich wieder alles beruigt hat.

[1999]

Hi.

Meiner Meinung nach kann man mit einem Kauf derzeit nicht viel verkehrt machen. Billiger kanns eigentlich kaum noch werden und auch der Chart schreit geradezu nach einer Gegenreaktion. Meine Vermutung ist ohnehin, daß die Biotechs von einer (hoffentlich baldigen!) Nasdaqerholung überproportional partizipieren werden. Hier ist einfach mal noch einiges mehr an Fantasie drin, als an den scheinbar nie proftiabel werdenden Internetwerten. Und daß die Stemmis hier eher markteng sind... naja, das muß ja kein Nachteil sein.

Bin jedenfalls ab heute mit 2,10 dabei. (Allerdings die Shares in Frankfurt, 889118)

Bye,
1999